

Edgar Filing: GRANT VENTURES INC - Form NT 10-Q

GRANT VENTURES INC  
Form NT 10-Q  
November 16, 2004

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number 000-50133

NOTIFICATION OF LATE FILING

Form 10-K             Form 11-K             Form 20-F             Form 10-Q  
 Form N-SAR

For Period Ended: September 30, 2004

Transition Report on Form 10-K             Transition Report on Form 10-Q  
 Transition Report on Form 20-F             Transition Report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

-----

PART I  
REGISTRANT INFORMATION

Full name of registrant	Grant Life Sciences, Inc.
Former name if applicable	Grant Ventures, Inc.
Address of principal executive office	5511 Capital Center Drive, Suite 224
City, state and zip code	Raleigh, North Carolina 27606

PART II  
RULE 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form 10-Q, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III  
NARRATIVE

## Edgar Filing: GRANT VENTURES INC - Form NT 10-Q

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

The registrant is in the process of preparing and reviewing the financial information of the Company on a consolidated basis. The process of compiling and disseminating the information required to be included in the Form 10-QSB for the relevant fiscal quarter, as well as the completion of the required review of the Company's financial information on a consolidated basis, could not be completed without incurring undue hardship and expense. The registrant undertakes the responsibility to file such quarterly report no later than five days after its original date.

### PART IV OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

John C. Wilson	(919)	852-4482
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

Yes       No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes       No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

For the quarter ended September 30, 2004, the registrant had no revenues and a net loss of approximately \$460,400. For the quarter ended September 30, 2003, the registrant had no revenues and a net loss of approximately \$65,800. Results for the quarter ended September 30, 2004 remain subject to further adjustment and actual results may differ significantly from the foregoing estimates.

The \$65,800 loss for the quarter ended September 30, 2003 is the net loss of Impact Diagnostics, Inc., now a wholly owned subsidiary of the Company. The Company acquired Impact Diagnostics on July 30, 2004.

Grant Life Sciences, Inc.  
Name of Registrant as Specified in Charter.

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Edgar Filing: GRANT VENTURES INC - Form NT 10-Q

Date: November 16, 2004

By /s/ John C. Wilson

-----  
John C. Wilson  
Chief Financial Officer